US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Turn Therapeutics (Direct Listing)

4.31

+0.06001.41%

Post-market: 4.310.00000.00%19:47 EST

Volume:59.42K

Turnover:255.41K

Market Cap:126.91M

PE:-31.27

High:4.40

Open:4.23

Low:4.21

Close:4.25

52wk High:26.50

52wk Low:2.57

Shares:29.45M

Float Shares:17.87M

Volume Ratio:1.17

T/O Rate:0.33%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1378

EPS(LYR):-0.0659

ROE:-2324.83%

ROA:-78.67%

PB:251.79

PE(LYR):-65.43

Loading ...

Overview Company News Filings

Director Arthur F. Golden Reports Acquisition of Turn Therapeutics Inc. Common Shares

Turn Therapeutics Inc. Officer Zuraiz Chaudhary Reports Acquisition of Common Shares

Interim CFO Zuraiz Chaudhary Acquires Common Shares of Turn Therapeutics Inc

Turn Therapeutics Reports Third Quarter Net Loss of $1.9 Million

Turn Therapeutics Qtrly EPS $-0.07

THOMSON REUTERS

Turn Therapeutics' GX-03 Named Top Innovation in Atopic Dermatitis Treatment

Turn Therapeutics CEO Discusses Restoring Public Trust in Science with Former CDC Director

Turn Therapeutics Names Andrew Scott Vice President of Corporate Communications

Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications

THOMSON REUTERS

Turn Therapeutics Enters Global Supply, Development, and License Agreement With Leading Medical-Surgical Product Manufacturer and Distributor Medline

THOMSON REUTERS

Turn Therapeutics Inc - Financial Terms and Timelines Confidential

THOMSON REUTERS

Board Observer Chesed Abraham Reports Acquisition of Turn Therapeutics Inc. Common Shares

Turn Therapeutics Partners with Medline for Global Expansion

Turn Therapeutics Signs Global Supply and Development Agreement with Medline Industries

Turn Therapeutics Inc. Officer Zuraiz Chaudhary Reports Acquisition of Common Shares

Turn Therapeutics Director Arthur F. Golden Reports Acquisition of Common Shares

Turn Therapeutics Updates Shareholders on Clinical Progress

BRIEF-Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones

Turn Therapeutics Advances Phase 2 Trial of GX-03 for Eczema Treatment

Turn Therapeutics launches webinar series for shareholder engagement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TTRX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TTRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TTRX\",,,,,undefined,":{"symbol":"TTRX","market":"US","secType":"STK","nameCN":"Turn Therapeutics (Direct Listing)","latestPrice":4.31,"timestamp":1764968400000,"preClose":4.25,"halted":0,"volume":59415,"hourTrading":{"tag":"盘后","latestPrice":4.31,"preClose":4.31,"latestTime":"19:47 EST","volume":144,"amount":617.18,"timestamp":1764982078495},"delay":0,"floatShares":17868800,"shares":29445200,"eps":-0.137821,"marketStatus":"Market Closed","change":0.06,"latestTime":"12-05 16:00:00 EST","open":4.23,"high":4.4,"low":4.21,"amount":255414.27146999998,"amplitude":0.044706,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.137821,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"listingDate":1759896000000,"exchange":"NASDAQ","adjPreClose":4.25,"preHourTrading":{"tag":"盘前","latestPrice":4.22,"preClose":4.25,"latestTime":"08:15 EST","volume":5,"amount":21.1398,"timestamp":1764940514982},"postHourTrading":{"tag":"盘后","latestPrice":4.31,"preClose":4.31,"latestTime":"19:47 EST","volume":144,"amount":617.18,"timestamp":1764982078495},"volumeRatio":1.172735952363409},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TTRX\",,,,,undefined,":{"symbol":"TTRX","floatShares":17868800,"roa":"-78.67%","roe":"-2324.83%","lyrEps":-0.065873,"volumeRatio":1.172735952363409,"shares":29445200,"dividePrice":0,"high":4.4,"amplitude":0.044706,"preClose":4.25,"low":4.21,"week52Low":2.5701,"pbRate":"251.79","week52High":26.5,"institutionHeld":0,"latestPrice":4.31,"eps":-0.137821,"divideRate":0,"volume":59415,"delay":0,"ttmEps":-0.137821,"open":4.23,"prevYearClose":10,"prevWeekClose":3.52,"prevMonthClose":3.52,"prevQuarterClose":10,"fiveDayClose":3.52,"twentyDayClose":4.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TTRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TTRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TTRX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TTRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TTRX","date":"2025-12-05","current":-31.272448,"percent":0.7,"low":-100.764104,"twenty":-57.391729,"median":-47.315318,"eighty":-27.302265,"high":-21.019642,"avg":-46.609795,"sd":17.548011,"marketCap":125142027},"quantilePoints":[{"date":"2025-10-10","current":-100.764104,"twenty":-95.944951,"median":-88.716222,"eighty":-81.487493,"marketCap":257809999},{"date":"2025-10-17","current":-61.772777,"twenty":-80.611283,"median":-71.301556,"eighty":-62.49565,"marketCap":158048738},{"date":"2025-10-24","current":-54.215469,"twenty":-75.594983,"median":-58.815569,"eighty":-54.127848,"marketCap":138712988},{"date":"2025-10-31","current":-57.391729,"twenty":-70.118673,"median":-57.391729,"eighty":-54.25928,"marketCap":146839608},{"date":"2025-11-07","current":-46.548635,"twenty":-64.664269,"median":-55.529784,"eighty":-49.111548,"marketCap":119097010},{"date":"2025-11-14","current":-44.796216,"twenty":-60.918473,"median":-54.215469,"eighty":-46.701972,"marketCap":114613358},{"date":"2025-11-21","current":-21.019642,"twenty":-57.501255,"median":-52.517813,"eighty":-44.182869,"marketCap":79796445},{"date":"2025-11-28","current":-27.302265,"twenty":-57.501255,"median":-48.301054,"eighty":-27.302265,"marketCap":103647044},{"date":"2025-12-05","current":-32.964383,"twenty":-57.391729,"median":-47.315318,"eighty":-27.302265,"marketCap":125142027}],"updateTime":1765113137485},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TTRX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586496163","title":"Director Arthur F. Golden Reports Acquisition of Turn Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586496163","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586496163?lang=en_us&edition=fundamental","pubTime":"2025-11-25 00:20","pubTimestamp":1764001222,"startTime":"0","endTime":"0","summary":"Arthur F. Golden, a director of Turn Therapeutics Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL5jBsHY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Arthur F. Golden Reports Acquisition of Turn Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4007"],"gpt_icon":0},{"id":"2585998121","title":"Turn Therapeutics Inc. Officer Zuraiz Chaudhary Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585998121","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585998121?lang=en_us&edition=fundamental","pubTime":"2025-11-22 06:44","pubTimestamp":1763765067,"startTime":"0","endTime":"0","summary":"Zuraiz Chaudhary, an officer of Turn Therapeutics Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL6Sg0qK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Turn Therapeutics Inc. Officer Zuraiz Chaudhary Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"gpt_icon":0},{"id":"2584043636","title":"Interim CFO Zuraiz Chaudhary Acquires Common Shares of Turn Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2584043636","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584043636?lang=en_us&edition=fundamental","pubTime":"2025-11-18 10:24","pubTimestamp":1763432651,"startTime":"0","endTime":"0","summary":"Zuraiz Chaudhary, Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer, reported the acquisition of common shares of Turn Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL3mbZRJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Interim CFO Zuraiz Chaudhary Acquires Common Shares of Turn Therapeutics Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"gpt_icon":0},{"id":"2583560731","title":"Turn Therapeutics Reports Third Quarter Net Loss of $1.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583560731","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583560731?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:00","pubTimestamp":1763038829,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc. reported a net loss of $1.9 million for the three months ended September 30, 2025, compared to a net loss of $0.7 million for the same period in 2024. General and administrative expenses rose to $1.8 million from $0.5 million, mainly due to increased legal and advisory fees associated with the company's direct listing on Nasdaq. As of September 30, 2025, the company had $3.1 million in cash and cash equivalents, up from $0.9 million at the end of 2024. Turn Therapeutics began trading on Nasdaq on October 8, 2025, and expanded its board and executive team during the period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Glob","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL7Jj36W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4588","IE00B64PRP62.GBP","BK4585","LU2095319765.USD","IE00BGHQF748.EUR","BK4112","LU2210149790.SGD","LU0314104364.USD","LU2210150020.SGD","IE00BKPKM429.USD","BK4007","IE00B3QW5Z07.USD","NDAQ"],"gpt_icon":0},{"id":"2583598646","title":"Turn Therapeutics Qtrly EPS $-0.07","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598646","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583598646?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:00","pubTimestamp":1763038807,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA51HKVG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX","BK4007"],"gpt_icon":0},{"id":"2582375505","title":"Turn Therapeutics' GX-03 Named Top Innovation in Atopic Dermatitis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375505","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375505?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:12","pubTimestamp":1762949555,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc. announced that its GX-03 technology, a topical IL36/IL31 inhibitor, has been recognized as one of \"Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment\" by Patient Care Online Magazine. The company highlighted that GX-03 represents the first topical agent targeting IL-36, a key player in the inflammatory processes of atopic dermatitis, eczema, and psoriasis. Preclinical studies showed GX-03's ability to inhibit several targets, including IL-36 alpha, IL-31, IL-4, and IL-36 gamma. Turn Therapeutics stated that topline data from its lead program in severe eczema will be announced in early 2026. Research results have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL7cVkQw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"gpt_icon":0},{"id":"2582397951","title":"Turn Therapeutics CEO Discusses Restoring Public Trust in Science with Former CDC Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2582397951","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582397951?lang=en_us&edition=fundamental","pubTime":"2025-11-12 05:05","pubTimestamp":1762895111,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc.  CEO Bradley Burnam recently held an interview with Dr. Robert Redfield, M.D., former Director of the Centers for Disease Control and Prevention . Their conversation focused on healthcare communication, pandemic preparedness, and restoring public trust in science, with both leaders emphasizing the importance of fact-based reporting in public health. The interview, titled \"Redfield's Warning: Former CDC Director on COVID's Biggest Casualty-Trust in Science,\" is available on all major podcast platforms, YouTube, and the Turn Therapeutics IR Website. The full interview can be accessed at Turn Therapeutics IR Website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDL1sNYRc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","NDAQ","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","LU0314104364.USD","BK4007","LU2095319765.USD","TTRX","LU2210150020.SGD"],"gpt_icon":0},{"id":"2581760449","title":"Turn Therapeutics Names Andrew Scott Vice President of Corporate Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=2581760449","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581760449?lang=en_us&edition=fundamental","pubTime":"2025-11-05 06:07","pubTimestamp":1762294054,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc. has appointed Andrew Scott as Vice President of Corporate Communications. In this role, Scott will oversee investor relations, capital markets strategy, and corporate communications, as well as support the company's licensing and partnership initiatives. Scott brings over 30 years of experience in capital markets and corporate finance, previously serving at ThinkEquity LLC and Fortress Biosciences, Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL4BDDtB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4585","BK4588","TTRX","NDAQ","LU2210150020.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2581470760","title":"Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=2581470760","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581470760?lang=en_us&edition=fundamental","pubTime":"2025-11-05 06:07","pubTimestamp":1762294046,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA30PF7N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX"],"gpt_icon":0},{"id":"2579478148","title":"Turn Therapeutics Enters Global Supply, Development, and License Agreement With Leading Medical-Surgical Product Manufacturer and Distributor Medline","url":"https://stock-news.laohu8.com/highlight/detail?id=2579478148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579478148?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:30","pubTimestamp":1761823801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUAB274NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX"],"gpt_icon":0},{"id":"2579148426","title":"Turn Therapeutics Inc - Financial Terms and Timelines Confidential","url":"https://stock-news.laohu8.com/highlight/detail?id=2579148426","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579148426?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:30","pubTimestamp":1761823801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUAB274NJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX"],"gpt_icon":0},{"id":"2579151621","title":"Board Observer Chesed Abraham Reports Acquisition of Turn Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2579151621","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579151621?lang=en_us&edition=fundamental","pubTime":"2025-10-30 08:43","pubTimestamp":1761785025,"startTime":"0","endTime":"0","summary":"Chesed Abraham, Board Observer, has reported the acquisition of common shares of Turn Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL3VhYvH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX"],"gpt_icon":0},{"id":"2579992196","title":"Turn Therapeutics Partners with Medline for Global Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2579992196","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579992196?lang=en_us&edition=fundamental","pubTime":"2025-10-29 04:38","pubTimestamp":1761683888,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc ( ($TTRX) ) has shared an update. On October 27, 2025, Turn Therapeutics, Inc. entered into a Global Supply, Development, and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-partners-with-medline-for-global-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-partners-with-medline-for-global-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","TTRX","BK4539","BK4007"],"gpt_icon":0},{"id":"2579399184","title":"Turn Therapeutics Signs Global Supply and Development Agreement with Medline Industries","url":"https://stock-news.laohu8.com/highlight/detail?id=2579399184","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579399184?lang=en_us&edition=fundamental","pubTime":"2025-10-29 04:08","pubTimestamp":1761682087,"startTime":"0","endTime":"0","summary":"Turn Therapeutics, Inc. announced that it has entered into a Global Supply, Development, and License Agreement with Medline Industries, LP. Under the agreement, Turn and Medline will collaborate to develop, manufacture, and commercialize health products utilizing Turn's proprietary PermaFusion delivery platform. Medline will handle global commercialization and distribution across its professional and retail networks, while Turn will provide formulation expertise, intellectual property, and clinical development capabilities. The agreement has an initial term of three years and will automatically renew for successive one-year periods unless either party provides written notice of non-renewal at least 120 days before the end of the current term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL4htRHM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX"],"gpt_icon":0},{"id":"2577255918","title":"Turn Therapeutics Inc. Officer Zuraiz Chaudhary Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2577255918","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577255918?lang=en_us&edition=fundamental","pubTime":"2025-10-24 09:04","pubTimestamp":1761267864,"startTime":"0","endTime":"0","summary":"Zuraiz Chaudhary, an officer at Turn Therapeutics Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL6qrDLd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX"],"gpt_icon":0},{"id":"2577559966","title":"Turn Therapeutics Director Arthur F. Golden Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2577559966","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577559966?lang=en_us&edition=fundamental","pubTime":"2025-10-24 09:02","pubTimestamp":1761267729,"startTime":"0","endTime":"0","summary":"Arthur F. Golden, Director, reported the acquisition of common shares of Turn Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL2ZCLQp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Turn Therapeutics Director Arthur F. Golden Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX"],"gpt_icon":0},{"id":"2577362300","title":"Turn Therapeutics Updates Shareholders on Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2577362300","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577362300?lang=en_us&edition=fundamental","pubTime":"2025-10-22 20:35","pubTimestamp":1761136540,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc ( ($TTRX) ) has provided an announcement. On October 22, 2025, Turn Therapeutics provided a shareholder update, highlighting ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-updates-shareholders-on-clinical-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-updates-shareholders-on-clinical-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","BK4097","BK4539","TTRX","LU2065732104.USD","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2577614543","title":"BRIEF-Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2577614543","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577614543?lang=en_us&edition=fundamental","pubTime":"2025-10-22 20:14","pubTimestamp":1761135277,"startTime":"0","endTime":"0","summary":"BRIEF-Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic MilestonesOct 22 (Reuters) - Turn Therapeutics Inc TTRX.O:TURN THERAPEUTICS PROVIDES ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nTUABNKTXR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX"],"gpt_icon":0},{"id":"2577369714","title":"Turn Therapeutics Advances Phase 2 Trial of GX-03 for Eczema Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2577369714","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577369714?lang=en_us&edition=fundamental","pubTime":"2025-10-22 20:00","pubTimestamp":1761134417,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc. has provided an update on its ongoing clinical development programs, including the phase 2 randomized, double-blind, placebo-controlled trial of GX-03, a topical IL-36/IL-31 inhibitor being evaluated as a potential treatment for moderate to severe eczema. According to the company, approximately 25% of the targeted sample size has completed the trial, with over 1,000 total confirmed applications of the study product or placebo and no safety or tolerability concerns reported so far. Topline results from the GX-03 study are anticipated in 2026. Additionally, Turn Therapeutics announced that in-vivo studies for its thermostable intranasal vaccine initiative are scheduled to commence in the fourth quarter of 2025. No final results from these studies have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDLbfB1j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","BK4588","IE00BGHQF748.EUR","LU2210149790.SGD","BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","TTRX","LU2095319765.USD","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2576549928","title":"Turn Therapeutics launches webinar series for shareholder engagement","url":"https://stock-news.laohu8.com/highlight/detail?id=2576549928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576549928?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:31","pubTimestamp":1760963465,"startTime":"0","endTime":"0","summary":"Turn Therapeutics (TTRX) announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders and a for...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/turn-therapeutics-launches-webinar-series-for-shareholder-engagement-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/turn-therapeutics-launches-webinar-series-for-shareholder-engagement-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","TTRX","BK4007","BK4539"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}]}}